New Zealand markets open in 8 hours 24 minutes

Finch Therapeutics Group, Inc. (FNCH)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
2.4550+0.1850 (+8.15%)
As of 09:36AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close2.2700
Open2.4500
Bid0.0000 x 0
Ask2.4100 x 100
Day's range2.4000 - 2.5099
52-week range1.8600 - 16.7400
Volume10,851
Avg. volume31,741
Market cap3.942M
Beta (5Y monthly)0.46
PE ratio (TTM)N/A
EPS (TTM)-46.5900
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est90.00
  • Insider Monkey

    Billionaire Seth Klarman’s Biotech Stock Picks

    In this article, we discuss billionaire Seth Klarman’s biotech stock picks. To skip the detailed analysis of the biotech industry, Seth Klarman’s investment philosophy, and Baupost Group’s performance and Q3 bets, go directly to Billionaire Seth Klarman’s Top 4 Biotech Stock Picks. Biotechnology is the technology segment that utilizes cellular and biomolecular processes for the […]

  • GlobeNewswire

    Finch Announces Reverse Stock Split of Common Stock

    BOSTON, June 09, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch”, “Finch Therapeutics” or the “Company”) (Nasdaq: FNCH), a microbiome technology company with a portfolio of intellectual property and microbiome assets, today announced it will effect a one-for-30 reverse stock split of its issued and outstanding common stock. Finch stockholders approved an amendment to its Amended and Restated Certificate of Incorporation to effect the reverse stock split at Finch’s Annual Meeting

  • GlobeNewswire

    Finch Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates

    SOMERVILLE, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch”, “Finch Therapeutics” or the “Company”) (Nasdaq: FNCH), a microbiome technology company with a portfolio of intellectual property and microbiome assets, today reported first quarter 2023 financial results and provided business updates. “Finch has continued to execute on its strategy to advance its novel microbiome technology through partnerships and collaborations, highlighted by the recent investigator-s